Failure rate

PayBito's Online Franchise Business Opens New Opportunities for Entrepreneurs

Retrieved on: 
Tuesday, May 30, 2023

PALO ALTO, Calif., May 30, 2023 /PRNewswire-PRWeb/ -- The US-based global crypto exchnage PayBito has opened new opportunities for entrepreneurs and individuals looking forward to opening an online franchise business. By providing a new business platform, the US-based crypto exchnage platform aims to allow entrepreneurs, individual brokers, and investors to venture into a business and leverage the expertise of an already established brand.

Key Points: 
  • PayBito, a US-based cryptocurrency exchange platform, has recently launched an exciting online franchise business opportunity catering to individuals, entrepreneurs, and business owners.
  • PALO ALTO, Calif., May 30, 2023 /PRNewswire-PRWeb/ -- The US-based global crypto exchnage PayBito has opened new opportunities for entrepreneurs and individuals looking forward to opening an online franchise business .
  • A Broker Platform As an Online Franchise Business:
    With a rise in startups, building an online franchise business with an established business is an added advantage.
  • With its online franchise business , PayBito is fuelling crypto adoption among businesses and encouraging young entrepreneurs, and investors to venture into the space.

Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm

Retrieved on: 
Tuesday, January 17, 2023

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm will commercialize, subject to regulatory review and approval, AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian Authority.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm will commercialize, subject to regulatory review and approval, AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian Authority.
  • “This agreement with Neopharm is an important step towards expanding AMX0035’s availability in the EMEA (Europe, Middle East, and Africa) region, if approved,” said Stéphanie Hoffmann-Gendebien, General Manager and Head of EMEA at Amylyx.
  • “The addition of AMX0035 to our portfolio and the opportunity to serve the ALS community in Israel and beyond is an honor,” said Efi Shnaidman, General Manager of Neopharm Israel.
  • “We look forward to working with Amylyx to serve people living with ALS who may benefit from this important new treatment option.”
    Under the terms of the agreement, Neopharm will receive exclusive rights to commercialize AMX0035 in the covered territory and will be responsible for all regulatory filings and obligations required for the registration and reimbursement of AMX0035.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.

Inspira™ Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Retrieved on: 
Thursday, December 22, 2022

ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N.

Key Points: 
  • ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N.
  • Ltd. (Nasdaq: IINN) ( Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET).
  • The RedChip Money Report® is produced by RedChip Companies Inc., an international investor relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™.
  • "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System

Retrieved on: 
Thursday, November 17, 2022

The LifeSPARC pump and controller system simplifies ECMO to ensure that hospitals of all sizes can access this high level of life support.

Key Points: 
  • The LifeSPARC pump and controller system simplifies ECMO to ensure that hospitals of all sizes can access this high level of life support.
  • The LifeSPARC controller was designed to remove complexity often seen with ECMO devices, instead offering a streamlined user interface and simple navigation panel.
  • LifeSPARC received an initial 510(k) FDA clearance in July 2019 for up to six hours of use for cardiopulmonary bypass.
  • The LifeSPARC System was built on more than 20 years of life support experience with TandemHeart, the first-generation ACS system.

Global Airway Management Devices Market to 2030 - Featuring Smiths Medical, Teleflex, Ambu and Convatec Group Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022

The global airway management devices market size is expected to reach USD 3.21 billion by 2030, according to a new study.

Key Points: 
  • The global airway management devices market size is expected to reach USD 3.21 billion by 2030, according to a new study.
  • The primary causes of the increase in the demand for airway management devices are the increasing number of respiratory emergencies and chronic obstructive pulmonary disease (COPD).
  • Companies competing in the global airway management market are focusing on creating solutions that are patient-friendly.
  • The publisher has segmented the airway management devices market report based on product type, age, end-use, and region:
    Airway Management Devices, Product Type Outlook (Revenue - USD Billion, 2018 - 2030)

Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis

Retrieved on: 
Monday, October 10, 2022

The first interim analysis was triggered 12 weeks after approximately one-third or more of the intended number of patients were randomized to participate in COURAGE-ALS.

Key Points: 
  • The first interim analysis was triggered 12 weeks after approximately one-third or more of the intended number of patients were randomized to participate in COURAGE-ALS.
  • The first interim analysis assessed for futility, 12 weeks after approximately one-third or more of the planned sample size is randomized.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

Retrieved on: 
Tuesday, September 27, 2022

In comparison, the epi 0.3mg IM injection Cmax was 489 pg/mL after one dose and 911 pg/mL after two doses.

Key Points: 
  • In comparison, the epi 0.3mg IM injection Cmax was 489 pg/mL after one dose and 911 pg/mL after two doses.
  • After one dose of AQST-109, maximum mean effects on systolic blood pressure occurred within 5 minutes of dosing compared to 8 minutes for EpiPen.
  • Maximum mean effects in heart rate occurred within 8 minutes of administering AQST-109 compared to an average of 5 minutes within administering EpiPen.
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

ReddyPort® Elbow Provides Access Without Risking Loss of Therapeutic Pressures or Lung Compliance

Retrieved on: 
Tuesday, September 13, 2022

ReddyPort products promote NIV success by empowering clinicians with efficient access to provide standardized oral care without removing the mask or loss of therapeutic pressures.

Key Points: 
  • ReddyPort products promote NIV success by empowering clinicians with efficient access to provide standardized oral care without removing the mask or loss of therapeutic pressures.
  • At the core of the ReddyPort system is our proprietary elbow withself-sealing valve thatprovides seamless oral accesstothepatient'smouth without risking loss of therapeutic pressures or lung compliance.
  • The ReddyPort Elbow is uniquely compatible with ReddyPort NIV appliances which allow cleaning and moisturizing of the patient's mouth without mask removal.
  • ReddyPort provides solutions for NIV patients to improve satisfaction, reduce risk and cost, enable better workflows, and enhance quality of care.

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS

Retrieved on: 
Thursday, September 8, 2022

The CENTAUR trial data has consistently demonstrated potential benefits of AMX0035 on function and overall survival.

Key Points: 
  • The CENTAUR trial data has consistently demonstrated potential benefits of AMX0035 on function and overall survival.
  • ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord.
  • Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death.
  • The PCNSDAC recommendations, while not binding, will be considered by the FDA in its review of the pending New Drug Application (NDA) for AMX0035.